Methods of using substituted pyrazole and pyrazole compounds and for treatment of hyperproliferative diseases

A technology for proliferative diseases and compounds, applied in drug combination, organic chemistry, pharmaceutical formulation, etc., can solve problems such as low efficiency

Inactive Publication Date: 2020-02-07
BANTAM PHARMA LLC
View PDF2 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Cancer cells can reprogram their glucose metabolism, and thus their energy production, by limiting most of their energy metabolism to glycolysis, a reprogramming that was considered primitive and inefficient by early biochemists.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods of using substituted pyrazole and pyrazole compounds and for treatment of hyperproliferative diseases
  • Methods of using substituted pyrazole and pyrazole compounds and for treatment of hyperproliferative diseases
  • Methods of using substituted pyrazole and pyrazole compounds and for treatment of hyperproliferative diseases

Examples

Experimental program
Comparison scheme
Effect test

example

[0347] General synthetic method

[0348] There are many general references available that provide generally known chemical synthesis schemes and conditions that can be used to synthesize the disclosed compounds (see, for example, Smith and March, "March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structures (March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure), Fifth Edition, Wiley-Interscience, 2001; or Vogel, A Textbook of Practical Organic Chemistry, Including Qualitative Organic Analysis (ATextbook of Practical Organic Chemistry, Including Qualitative Organic Analysis), Fourth Edition, New York (New York): Longman (Longman, 1978).

[0349] The compounds described herein can be purified by any means known in the art, including chromatography, such as HPLC, preparative thin layer chromatography, flash column chromatography, and ion exchange chromatography. Any suitable stationary phase can be used, including normal phase and reverse phase and i...

example 1

[1153] Example 1: Anti-cancer activity

[1154] A group of 96 tumors and 3 normal cell lines were tested for their sensitivity to the test compound. Culture these cell lines in standard medium and pipette them into 96-well plates at the desired plating density. Before compound testing, the cells were allowed to acclimate for 24 hours. Prepare a 20 mM stock solution of the compound in DMSO. To prepare a dose response curve, the compound was serially diluted in DMSO and dispensed into each well of the plate using a Tecan D300e digital dispenser. The final DMSO concentration is 0.15%. After 72 hours of incubation, use (Promega) protocol to determine the number of cells. In this analysis, ATP is measured as a substitute for cell number. The activity of the compound is determined by comparing untreated cells with treated cells and calculating the percentage of signal retained. Compound activity is EC at maximum efficacy level 50 These two values ​​are measured and used to calc...

example 2

[1164] Example 2: The effect of KRAS on activity

[1165] Next, the genotype of the KRAS allele in the solid tumor line was determined. Using the COSMIC database, KRAS genotype and zygosity (homozygous or heterozygous) can be determined for 74 of 77 solid tumor cell lines (Table 3).

[1166] Table 3. Tumor responsiveness regarding KRAS genotype

[1167]

[1168] Only 20% of cell types with wild-type KRAS alleles responded to the test compound. In contrast, 65% of cell types with mutations in the KRAS allele responded to the test compound. When the analysis was extended to whether the KRAS allele was homozygous or heterozygous, the results were significantly different (Table 4). in KRAS Cell lines with heterozygous mutations in alleles showed the greatest reactivity.

[1169] Table 4. Tumor responsiveness regarding KRAS zygosity

[1170]

[1171]

[1172] The final analysis on the role of KRAS in the reaction to the test compounds used compiles data based on the active area of ​​th...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Disclosed are methods of treating hyperproliferative disorders such as cancer, methods of arresting the cell cycle in cancer cells, methods of inhibiting glutathione synthesis in cancer cells, and associated compounds for use and uses in medicaments. In certain embodiments, the methods, uses and compounds are provided with reference to compounds of the structural formula (I), in which X1, X2, Z1,Z2, the ring system denoted by "a", R1, L1, L2, Q, L3, R3, L4, R4, L5, and R5 are as described herein. In certain embodiments, compounds disclosed herein are especially active against cancers having amutant KRAS gene.

Description

[0001] Cross references to related applications [0002] This application claims the priority rights of U.S. Provisional Application Patent No. 62 / 428,274 filed on November 30, 2016, which is hereby incorporated by reference in its entirety. Technical field [0003] The present disclosure relates to the field of compounds, pharmaceutical compositions including the compounds, and methods of using the compounds and compositions. More specifically, the present disclosure relates to methods of using certain compounds to treat hyperproliferative disorders such as cancer. Background technique [0004] Cancer is uncontrolled cell proliferation and is a multifactorial disease characterized by tumor formation, growth, and in some cases metastasis. In the United States, more than 1.5 million people will be diagnosed with cancer this year, and more than 500,000 people will die of cancer. Overall, it is estimated that at least one in three people will develop some form of cancer in their life...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/427C07D417/04
CPCA61K31/427A61P35/00A61K31/437A61K31/4439A61K31/454A61K31/506A61K31/519A61K31/5377
Inventor M.A.西迪奎S.西布拉特L.康斯坦帝诺-福格特C.格兰德-梅特小X.郭S.斯里瓦斯塔瓦G.W.希普斯A.B.库珀V.奥扎M.科斯图拉M.卢瑟J.莱文
Owner BANTAM PHARMA LLC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products